PVR is associated with resistance to anti-PD-1 immunotherapy [77], resulting in immune cell inhibition. In line with previous work, our data show that PVR expression is reduced when IL-15 complexes are combined with anti-PD-1 blockade, thereby, in part, lowering the cancer-immune set-point in the TME to better promote antitumor immunity. Here, IL15 is linked to cancer.